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Abstract
In a new mouse model for generalized pain syndrome, including fibromyalgia, which used
intermittent cold stress (ICS), bilateral allodynia in the hindpaw was observed that lasted more than
12 days; thermal hyperalgesia lasted 15 days. During constant cold stress (CCS), mice showed only
a transient allodynia. A female prevalence in ICS-induced allodynia was observed in
gonadectomized but not in gonad intact mice. Systemic gabapentin showed complete anti-allodynic
effects in the ICS model at the one-tenth dose for injury-induced neuropathic pain model, and
central gabapentin showed long-lasting analgesia for 4 days in ICS, but not the injury model. These
results suggest that the ICS model is useful for the study of generalized pain syndrome.
Findings
Fibromyalgia syndrome (FMS) is a highly prevalent (~2%
of all citizens) chronic pain disease, which has unique
characteristics including generalized or widespread allo-
dynia and a female preponderance [1-4]. According to
recent reports, physical and psychological stressors are
believed to trigger FMS [5-9]. Although there are several
trials underway to make existing medicines available for
FMS treatment, attempts to develop a compound specific
for FMS are yet to be performed. One reason is the lack of
established experimental animal models for FMS,
although several models have been proposed [10-13].
Here, we report a pharmacological study using a new gen-
eralized chronic pain or FMS model, using intermittent
cold stress.
We improved the mouse model for dysautonomia, also
referred to as the specific alternation of rhythm in temper-
ature (SART) model [14,15]. To develop the stress model
of mice with reproducible and long-lasting allodynia and
hyperalgesia, we evaluated several different stress para-
digms. With regard to a temperature of the cold room, the
temperature of 4 ± 2°C gave rise to long-lasting allodynia.
At the temperature over 6°C, long-lasting and stable allo-
dynia was not observed. For quick changes in temperature
between 4 and 24°C, we used a meshed stainless steel
floor in each cage, and transferred mice individually, leav-
ing the stainless floor in the cold room. Trials with differ-
ent numbers of mice in the same cage, ranging from one
to eight mice, revealed that the number of mice in the
same cage should be two. Although frequent temperature
change is expected to be more stressful, an interval of
more than 30 min was estimated to be minimal for the
switch between 4 and 24°C. To maintain healthy condi-
tions in the cold room, food pellets and gelatin as the
water supply were placed on the floor of the cage in the
cold room, owing to the lowered spontaneous activities of
mice in such conditions. For stable nociception, an adap-
tation period of at least 1 h before the nociception tests
was necessary.
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In the paw pressure test using the digital von Frey appara-
tus, the control pre-stress threshold of the right paw was
9.5 ± 0.2 g (n = 6), as shown in Fig. 1A. On the other hand,
the threshold at day 3 (P1) was significantly decreased to
5.4 ± 0.2 g. Similar thresholds were also found for the left
paw, and decreased thresholds on both sides lasted until
at least P12 (Figs. 1A, 1B). When CCS was performed, the
threshold at P1 was significantly lower (6.1 ± 0.4 g, n = 5)
than in the control mice, but no significant change was
observed at P5 or P12 (Fig. 1A).
Gonadectomy had no significant influence on the gross
behavioral activities. Furthermore, there was no signifi-
cant change in the control nociceptive threshold in the
paw pressure test at 3 weeks after gonadectomy (male: 9.8
± 0.3 g, female: 9.6 ± 0.3 g). To determine the effects of
gonadectomy (or sham operation) on ICS-induced
mechanical allodynia, the changes in threshold were
determined by subtracting the post-ICS level from the
control level (decrease in threshold). As shown in Fig. 1C,
the ICS-induced decrease in threshold was 4.5 ± 0.1 g and
4.2 ± 0.2 g for males and females, respectively. There was
no apparent gender difference in ICS-induced allodynia.
Long-lasting and bilateral allodynia and hyperalgesia induced by ICS Figure 1
Long-lasting and bilateral allodynia and hyperalgesia induced by ICS. A, B: ICS-induced mechanical allodynia on the 
(A) right and (B) left hind paws. The paw pressure test, using digital von Frey apparatus, was performed at pre-stress (day 0) 
and at P1, 5 and 12 (days 3, 7 and 14) after ICS/CCS. C: Effects of gonadectomy on ICS-induced mechanical allodynia in male 
and female mice. Data represent the decrease in the threshold obtained by subtracting the threshold at P1 or P5 from the pre-
stress value. D: ICS-induced thermal hyperalgesia. Data represent the means ± S.E.M. from 4–6 individual mice per group. *p < 
0.05 versus control group. #p < 0.05 versus sham group.Molecular Pain 2008, 4:52 http://www.molecularpain.com/content/4/1/52
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However, the decrease in threshold after ICS was signifi-
cantly attenuated by gonadectomy of male mice, but not
female mice, at P1. Similar results were also observed at
P5. In the thermal paw withdrawal test, the control
threshold was 10.0 ± 0.2 sec in the thermal paw with-
drawal test. After ICS, the threshold was significantly
decreased to 5.8 ± 0.1 sec at P15. The degree of hyperalge-
sia was comparable to that seen in partial sciatic nerve
injury [16].
As shown in Fig. 2A, systemic administration of gabapen-
tin after ICS-treatments dose-dependently reversed the
ICS-decreased threshold at 0.5 h in the range of 0.3–3 mg/
kg (i.p.). Gabapentin showed significant analgesic effects
at 1 and 3 mg/kg in the ICS-model, and at 30 mg/kg in the
injury-induced neuropathic pain model. Significant anal-
gesia induced by 3 mg/kg gabapentin was observed at 0.5
and 3 h, but not at 24 or 48 h in the ICS model (Fig. 2B).
When gabapentin was administered i.c.v., complete
reversal of the ICS-decreased threshold at 0.5 h was
observed with 3 or 10 μg gabapentin, which was given at
P5 (Fig. 2C). However, no significant analgesia was
observed with 3 and 10 μg gabapentin in the injury
model. Over the time course of study of gabapentin
(i.c.v.) effects, complete and significant reversal of ICS-
decreased threshold was also observed at 48 and 96 h,
respectively (Fig. 2D). There was some, but not signifi-
cant, analgesia at 120 h.
In the present study, we demonstrated that intermittent
cold stress (ICS) causes abnormal pain, including
mechanical allodynia and hyperalgesia, which lasts for
more than 2 weeks. Although similar allodynia was also
observed at P1 after the constant or CCS, the threshold
was reversed to the normal level at P5. Thus, this long-last-
ing allodynia was specific for intermittent changes in tem-
perature. During the establishment of this model, we
examined several paradigms of changes in cold stress.
Analgesic effects of gabapentin in the ICS and neuropathic pain models Figure 2
Analgesic effects of gabapentin in the ICS and neuropathic pain models. A: Dose-dependent analgesia by gabapentin 
(i.p.). The paw pressure test was performed at 0.5 h after gabapentin injection at day 7 after ICS or nerve injury. B: Time 
course of gabapentin (3 mg/kg, i.p.) analgesia in the ICS model. C: Dose-dependent analgesia by gabapentin (i.c.v.). D: Time 
course of gabapentin (3 μg/kg, i.c.v.) analgesia in the ICS model. Data were normalized to the level in the control plus vehicle 
group. Data represent the means ± S.E.M. from 4–9 individual mice per group. *p < 0.05 versus control group. #p < 0.05 ver-
sus vehicle group.Molecular Pain 2008, 4:52 http://www.molecularpain.com/content/4/1/52
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From these attempts, we found that a low temperature for
the cold stress and a high frequency of temperature alter-
ations produced a long-lasting and stable allodynia. Based
on these results, we determined the optimum paradigm to
generate the generalized pain, producing a FMS model in
the mouse. This model has several advantages, as no spe-
cific apparatus, except for a conventional refrigerator for
medical use, is necessary, and the short period of stress
application (i.e., three nights) is sufficient to cause long-
lasting mechanical allodynia and thermal hyperalgesia.
There are several stress-induced generalized pain syn-
dromes, such as FMS, chronic fatigue syndrome, temporo-
mandibular jaw disorder and irritable bowel syndrome
[17]. These pain-related syndromes share a common fea-
ture with a female prevalence. In the present study, when
the male and female mice were gonadectomized, only
male mice showed reversal of ICS-induced allodynia.
There was no significant change in the threshold in female
mice. As gender hormones are still expected to exist in the
adrenal cortex, the endocrine homeostasis may compen-
sate for this endocrine disturbance, but it is not necessarily
correct that androgens may play roles in abnormal pain
caused by ICS stress. However, as the castration itself did
not affect the nociceptive threshold, some contributions
of androgens to the abnormal pain are likely to work
under the condition of ICS. Therefore, we speculate that
this ICS model has a gender hormone-independent
female predominance of chronic pain.
Of these pain syndromes described, the intensity of FMS
is the highest. In addition to the intensity, FMS is known
to have unique widespread allodynia. Indeed, we demon-
strated mechanical allodynia on both hind paws and
intense thermal hyperalgesia for long periods. All these
findings suggest that ICS-stress may be a good model for
FMS or related stress-induced pain syndromes, as men-
tioned above.
The second issue is the potent analgesic actions of gabap-
entin. Gabapentin is now widely used as a potent analge-
sic against neuropathic pain. Because of its chemical
instability, higher doses are required in clinical use. In the
present study, we confirmed that relatively high doses
(10–30 mg/kg i.p.) of gabapentin significantly inhibited
nerve injury-induced neuropathic pain. Similar effective
doses were also observed in chemotherapy (paclitaxel)-
induced neuropathic pain in our previous study [18]. In
the ICS-model, however, a dose of gabapentin as low as 3
mg/kg (i.p.) was sufficient for the complete inhibition of
allodynia/hyperalgesia. It should be noted that central
administration of gabapentin also showed potent analge-
sia, but the analgesia persisted for 4–5 days after a single
injection. Gabapentin at 3 μg (i.c.v.) showed complete
analgesia in the ICS model, but not at 10 μg in the neuro-
pathic pain model, which is consistent with the previous
study that 100 μg of gabapentin is required for the com-
plete analgesia in the neuropathic pain model [19]. Thus
the abnormal pain in the ICS model mice provides a bet-
ter target for gabapentin than that in nerve injury- or pacl-
itaxel-induced neuropathic pain, in which 30 mg/kg of
gabapentin is required for complete analgesia [18]. How-
ever, it remains to be determined why a single injection of
gabapentin has such long-term effects.
Stress-induced pain, as in FMS, is considered to be caused
by intense events involving physical and psychological
injury and is reinforced by successive stress. In other
words, it develops into a vicious cycle of pain-induced
pain. Although the site of action for gabapentin analgesia
in the ICS model remains to be determined, initial block-
ade of the pain mechanisms may have relieved the succes-
sive cycle. Taking this notion into consideration, the site
of action of gabapentin in the ICS model seems to be in
the central nervous system. This view seems to be consist-
ent with the finding that a higher dose of central gabapen-
tin was required for nerve injury-induced neuropathic
pain than was the case with ICS model. However, this may
exclude the possibility that centrally administered gabap-
entin is quickly adsorbed in the brain tissues and slowly
released. According to recent studies, the most likely
molecular target is the α 2δ 1 subunit of a voltage-depend-
ent calcium channel [20-22]. Actually, we have demon-
strated up-regulation of this subunit expression in the
dorsal root ganglion, which may underlie the mecha-
nisms of gabapentin analgesia in the nerve injury- or pacl-
itaxel-induced neuropathic pain model [18]. It is of
interest to further examine if the up-regulation of the α 2δ
1 subunit is also involved in the potent gabapentin anal-
gesia in the ICS-model.
In conclusion, the present study demonstrates that the ICS
model is a promising candidate for experimental FMS or
generalized pain syndrome models. In addition, we found
beneficial effects of systemic and central gabapentin in
this model in terms of potency and duration.
Materials and methods
Animal treatments
Six-week-old male and female C57BL/6J mice weighing
18–22 g were used. These mice were individually kept in
a room maintained at 22 ± 2°C, humidity 60 ± 5% and ad
libitum feeding of a standard laboratory diet and tap water
before use. In the intermittent cold stress (ICS) model
experiments, two mice per group were kept in a cold room
at 4 ± 2°C at 4:30 p.m. on the first day (day 0), with ad
libitum  feeding and agar instead of water. Mice were
placed on a stainless steel mesh and covered with plex-
iglass cage. At 10:00 a.m. the next morning, mice were
transferred to the normal temperature room at 24 ± 2°C.Molecular Pain 2008, 4:52 http://www.molecularpain.com/content/4/1/52
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After they were placed at the normal temperature for 30
min, mice were put in the cold room again for 30 min.
These processes were repeated until 4:30 p.m Mice were
then put in the cold room overnight. After the same treat-
ments on the next day, mice were finally taken out from
the cold room at 10:00 a.m. on day 3 (post-stress P1) and
were kept there for adaptation before nociception tests,
which were started at least 1 h later. On the other hand, in
the constant or CCS model experiments, mice were kept
in the cold room without alternating the environmental
temperature for three consecutive nights. The body weight
of mice after either ICS or CCS stress, decreased by
approximately 10% after 2–3 days, but subsequently
recovered to the normal level of unstressed control mice
and throughout the experiments. In the neuropathic pain
model, nociception tests were carried out 1 week after the
partial ligation of sciatic nerve, as previously reported
[23]. All experiments were performed in compliance with
the relevant laws and institutional guidelines. All proce-
dures were approved by the Nagasaki University Animal
Care Committee and complied with the recommenda-
tions of the International Association for the Study of Pain
(Zimmermann, 1983).
Gonadectomy
Six-week-old male and female mice were gonadectomized
by removing ovaries or testes, respectively under pento-
barbital (50 mg/kg i.p.) anesthesia. After the surgery, mice
were kept in a soft bed cage with some food inside so that
the animals could feed themselves without difficulty in
standing. Gonadectomized mice were used for ICS and
nociception tests 3 weeks later.
Nociception tests
In most of the experiments, the paw pressure test was car-
ried out using a digital von Frey apparatus test (Anesthesi-
ometer, IITC Inc., Woodland Hills, USA), as previously
reported [16,24]. In this experiment, the threshold (in
grams) of given pressure to cause the paw withdrawal
behavior of mouse was evaluated. The maximum
response threshold was set at 20 g to prevent tissue dam-
age. In some experiments, the thermal paw withdrawal
test was carried out using a thermal stimulus (Model 33
Tail Flick analgesia meter, IITC Inc., Woodland Hills, CA,
USA), as previously reported [16,24]. A cut-off time was
set at 20 seconds to prevent tissue damage. Nociception
tests were performed between 12:00 and 4:30 p.m.
throughout experiments. The control threshold was deter-
mined immediately prior to the start of ICS or CCS (pre-
stress). Test thresholds were determined on days 3, 7 and
14, which were represented as post-stress day 1, 5 and 12
(P1, P5 and P12), respectively.
Drug treatment
Gabapentin, purchased from Sigma-Aldrich (St. Louis,
MO), was dissolved in physiological saline or artificial
cerebrospinal fluid (aCSF) for intraperitoneal (i.p.) or
intracerebroventricular (i.c.v.) treatments, respectively.
Gabapentin was given in a volume of 0.1 ml/10 g or 5 μl/
mouse for i.p. or i.c.v. injection on day 7 (P5).
Statistical analysis
All results are expressed as means ± S.E.M. Differences
between multiple groups were analyzed using a one-way
ANOVA with Scheffe's F multiple comparison post-hoc
analysis. Changes in the thresholds were analyzed using
an unpaired Student's t-test. The criterion of significance
was set at p < 0.05.
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